170,002 Shares in Immunome, Inc. $IMNM Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, HoldingsChannel reports. The firm acquired 170,002 shares of the company’s stock, valued at approximately $3,652,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after acquiring an additional 14,398 shares during the period. Creative Planning bought a new position in Immunome in the second quarter valued at $167,000. Rhumbline Advisers grew its position in Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after purchasing an additional 19,526 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Immunome by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after purchasing an additional 9,686 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Immunome in the second quarter valued at $1,021,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Price Performance

Shares of IMNM opened at $22.95 on Thursday. The firm has a 50-day moving average of $21.86 and a 200-day moving average of $20.72. Immunome, Inc. has a one year low of $7.15 and a one year high of $27.65. The company has a market cap of $2.60 billion, a PE ratio of -9.48 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Analysts expect that Immunome, Inc. will post -2.5 earnings per share for the current year.

Analyst Ratings Changes

IMNM has been the subject of a number of analyst reports. HC Wainwright initiated coverage on shares of Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research report on Thursday, January 15th. Craig Hallum raised their target price on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

Insider Activity

In other news, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the completion of the transaction, the chief financial officer owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This trade represents a 54.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 9,438 shares of Immunome stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the transaction, the insider directly owned 22,000 shares of the company’s stock, valued at approximately $476,080. This trade represents a 30.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,438 shares of company stock valued at $2,964,664 in the last quarter. Company insiders own 7.69% of the company’s stock.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.